These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38195842)

  • 1. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation.
    Gong TT; Liu FH; Xiao Q; Li YZ; Wei YF; Xu HL; Cao F; Sun ML; Jiang FL; Tao T; Ma QP; Qin X; Song Y; Gao S; Wu L; Zhao YH; Huang DH; Wu QJ
    Commun Biol; 2024 Jan; 7(1):67. PubMed ID: 38195842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.
    Zhu Y; Liang L; Zhao Y; Li J; Zeng J; Yuan Y; Li N; Wu L
    J Nanobiotechnology; 2024 Jan; 22(1):35. PubMed ID: 38243224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Noriega Rivera RA; Rivera YS; Tous-Beveraggi J; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
    Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD.
    Yang X; Sun D; Xiang H; Wang S; Huang Y; Li L; Cheng X; Liu H; Hu F; Cheng Y; Ma T; Hu M; Tian H; Tian S; Zhou Y; Zhang P; Zhang XJ; Ji YX; Hu Y; Li H; She ZG
    Hepatology; 2021 Sep; 74(3):1319-1338. PubMed ID: 33894019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SH3RF2 functions as an oncogene by mediating PAK4 protein stability.
    Kim TW; Kang YK; Park ZY; Kim YH; Hong SW; Oh SJ; Sohn HA; Yang SJ; Jang YJ; Lee DC; Kim SY; Yoo HS; Kim E; Yeom YI; Park KC
    Carcinogenesis; 2014 Mar; 35(3):624-34. PubMed ID: 24130170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling.
    Li M; Hu M; Wang Y; Xia Z; Li Z; Li J; Zheng D; Zheng X; Xi M
    Biochem Biophys Res Commun; 2022 Dec; 637():348-357. PubMed ID: 36423381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sh3rf2/POSHER protein promotes cell survival by ring-mediated proteasomal degradation of the c-Jun N-terminal kinase scaffold POSH (Plenty of SH3s) protein.
    Wilhelm M; Kukekov NV; Schmit TL; Biagas KV; Sproul AA; Gire S; Maes ME; Xu Z; Greene LA
    J Biol Chem; 2012 Jan; 287(3):2247-56. PubMed ID: 22128169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
    Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
    Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
    Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
    J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
    Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
    Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
    Cai L; Zhang Q; Du L; Zheng F
    Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J; Liu L
    J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer.
    Zheng Z; Li X; Yang B; Xu Q; Zhu X; Hu L; Teng Y
    Funct Integr Genomics; 2023 May; 23(2):147. PubMed ID: 37145301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
    Bahar E; Kim JY; Kim HS; Yoon H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.